81C6 ttTenascinAbatacept ttCTLA4ConjugateAbciximab ttGPIIAIIIBAdalimumab ttTNFalphaAIN457Alemtuzumab ttCD52AMD macular degenerationAMG386 ttAngiopoietin1 ttAngiopoietin2Antibodies (therapeutic use)Atacicept ttBlys ttAPRILBapineuzumab ttAmyloidBetaBasiliximab ttIL2RBelatacept ttCD80 ttCD86Belimumab ttBLySBevacizumab ttVEGFBrentuximab vedotin ttCD30Briakinumab ttIL12 ttIL23Canakinumab ttIL1betaCatumaxomab ttEpCAM ttCD3 linkerAbCertolizumab ttTNFalphaCetuximab ttEGFR
Daclizumab ttIL2RDalotuzumab ttIGF1RDenosumab ttRANKLEculizumab ttFactorHEfalizumab ttLFA1Epratuzumab ttCD22Etanercept ttTNFalphaEye (Central vein occlusion)Eye (Macula edema)Eye (Pharmacology)FactorIXFc ttFactorIXFactorVIIIFc ttFactorVIIIFarletuzumab ttFolateRalphaFigitumumab ttIGF1RGaliximab ttCD80Gemtuzumab ozogamicin ttCD33Girentuximab ttCarbonicAnhydraseIXGolimumab ttTNFalphaIbritumomab tiuxentan yttrium ttCD20Infliximab ttTNFalphaInotuzumab ozogamicin ttCD22
Ipilimumab ttCTLA4Mepolizumab ttIL5Motavizumab ttRSVirusMuromonabCD3 ttCD3Naptumomab estafenatox tt5T4Natalizumab ttIntegrinalpha4Necitumumab ttEGFRNimotuzumab ttEGFRObinutuzumab ttCD20Ocrelizumab ttCD20Ofatumumab ttCD20Omalizumab ttCD20Otelixizumab ttCD3Pagibaximab ttLipoteichoicAcidStaphlococcusPalivizumab ttRSVirusFproteinPanitumomab ttEGFRPegaptanibPertuzumab ttHER2Ramucirumab ttVEGFR2Ranibizumab ttVEGFRaxibacumab ttAnthrax
REGN88 ttIL6RReslizumab ttIL5Rilonacept ttIL1RRituximab ttCD20Solanezumab ttAmyloidBetaSorafenibSunitinibT1H ttCD6Tanezumab ttNGFTeplizumab ttCD3Tocilizumab ttIL6Tositumomab ttCD20Trastuzumab emtansine ttHER2Trastuzumab ttHER2Tremelimumab ttCLTA4Ustekinumab ttIL12 ttIL23Vedolizumab ttIntegrina4b7Zalutumumab ttEGFRZanulimumab ttCD4
Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth
All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.